
Containment Technology Forum: Applying ICH Q9 Principles to Selecting Containment Technology
3–4 December 2008
Barcelona, Spain
Seminar Leaders
Johannes Rauschnabel, Robert Bosch GmbH,
Daniel De Grande, De Grande Consulting,
- Develop successful solutions to current containment issues
- Consider assessment tools such as ICH Q9 and the new ISPE Risk-MaPP Baseline® Guide
- Establish a network to support you with on-the-job challenges – including an introduction to ISPE’s Containment Community of Practice (COP)
Increasing containment is necessary to minimise contamination of the operator environment and avoid cross-contamination from one product to the other. Each situation needs to be evaluated on a case-by-case basis, using risk assessment tools such as ICH Q9 and ISPE’s Risk-MaPP Baseline® Guide to identify the appropriate risk controls, as well as set health-based limits to address both cross-contamination and operator protection.
To select appropriate containment technology, a partnership of healthcare professionals with focus on identification of hazards, exposure assessments, risk evaluation and implementation of risk controls - as well as considering the economic and regulatory impact of non-compliance – and engineers has to be implemented.
Both, speakers from industry experts and subject matter experts will use a series of case studies, workshops and update sessions, to enable participants to develop successful solutions to current containment issues. 3 interactive workshops on given scenarios help to develop containment concepts “hands-on” and learn from each other. The seminar offers participants a great opportunity to establish a network of supporting resources for risk assessments and engineering for manufacturing pharmaceutical compounds in their work setting.
Take Back To Your Job
- An introduction to ISPE's Risk-MaPP Baseline Guide and ts application
- A clear understanding of hazard, risk and exposure and how they affect each other
- Practical learning from case studies including engineering, risk approach, process design, operational procedures and operator training through presentations and workgroups
- Successful solutions to current containment issues
- A tool kit to help select risk controls and engineered solutions that balance product quality and operator protection – including an introduction of the Containment COP
Agenda
Wednesday, 3 December
10.00 – 10.15 Welcome and Introduction
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
10.15 – 11.15 Containment Approach at Boehringer Ingelheim
Jürgen Fleckenstein, Boehringer Ingelheim (Germany)
- OEB determination at Boehringer Ingelheim
- GMP and containment
- Risk management
11.15 – 12.15 Case Study 1: Contained Facility for Enzyme Production
Bent Christensen, Novozymes (Denmark)
- Extreme OEL at high production volumes
12.15 – 13.45 Lunch and Networking Break
13.45 – 14.00 Introduction to Workgroup Tasks/Case Studies
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
Richard Denk, Hecht Anlagenbau (Germany)
- Three Case studies to be elaborated in four groups
14.00 – 15.45 Workgroups
Moderators: Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
Richard Denk, Hecht Anlagenbau (Germany)
- Case study 1: Containment for OSD manufacture
- Case study 2: Containment for sterile cytotoxics
- Case study 3: API manufacture
15.45 – 16.15 Coffee and Networking Break
16.15 – 16.30 Workgroups (continued)
Moderators: Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
Richard Denk, Hecht Anlagenbau (Germany)
- Case study 1: Containment for OSD manufacture
- Case study 2: Containment for sterile cytotoxics
- Case study 3: API manufacture
16.30 – 17.45 Presentation of Results
17.45 – 18.00 Questions and Answers, Close of Day 1
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
17.30 – 18.30 Networking Reception
Thursday, 4 December
09.00 – 09.15 Review of Day 1, Introduction to Day 2
Johannes Rauschnabel, Robert Bosch GmbH, (Germany)
Daniel De Grande, De Grande Consulting, (Belgium)
09.15 – 10.15 Aseptic Containments for Filling of Liquid Products
Mathias Kreher, Robert Bosch GmbH (Germany)
- GMP vs. IH
- Containment isolator
- Containment RABS
- Case studies
10.15 – 10.45 Coffee and Networking Break
10.45 – 11.45 Risk-MaPP – Applying a Risk-based Approach to the Manufacture of Pharmaceutical Products
Paul Wreglesworth, Astra Zeneca (UK)
- ISPE’s Risk-MaPP Baseline Guide
- Hazard vs. risk
- Science-based decision making
- When to dedicate or segregate
11.45 – 12.45 Case Study 2: Safety and Efficiency through Containment Manufacturing: NewCon project Illertissen/Germany
Holger Weyhers, Pfizer (Germany)
- Stay tuned for future session updates
12.45 – 14.15 Lunch and Networking Break
14.15 – 14.30 Introduction to ISPE and COP Containment
Kate McCormick, ISPE (UK)
Richard Denk, Hecht Anlagenbau (Germany)
14.30 – 15.15 Case Study 3: High Level Containment OEB5
Joost Nieuwlaat, JOA (Netherlands)
- Pros and cons of high level containment valves
- Impact to utilities, dedusting and process infrastructure
- Design considerations dedusting system
- Example integrated project approach vendor/end use
15.15 – 16.15 Questions and Answers, Close of Seminar
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
